Please provide your email address to receive an email when new articles are posted on . Herpes simplex keratitis is a challenge to diagnose and treat. My guest columnist this month is Sonal S. Tuli, ...

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...

In a recent study published in the Virology Journal, a group of researchers evaluated the antiviral efficacy and therapeutic potential of harmol in treating herpes simplex virus type 1 (HSV-1) induced ...

SAN FRANCISCO, April 22, 2024 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc. (“Excision”, the “Company”), a clinical-stage biotechnology company developing CRISPR-based therapies to cure serious ...

Researchers from Excision Biotherapeutics Inc. and affiliated organizations have reported the development of a novel CRISPR/Cas9-mediated genome editing therapy – EBT-104 – for the treatment of latent ...

- Treatment with EBT-104 led to complete elimination of viral shedding in 92% eyes of treated rabbits - Excision’s proprietary gene editing technology holds unique, curative potential to address the ...

Compr Ophthalmol Update. 2005;6(2):85-101. In a 10-week study of three times daily oral acyclovir against placebo, pediatric patients with HSV stromal keratitis who were treated concomitantly with ...

PITTSBURGH, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the United States Food and Drug Administration (FDA) granted platform technology ...

The U.S. Food and Drug Administration has granted Priority Review for Aicuris’ New Drug Application for pritelivir, a novel helicase primase ...

- Excision’s proprietary gene editing technology holds unique, curative potential to address the leading cause of corneal blindness in the United States - Global incidence of HSV keratitis is ...